Ascendis Pharma A/S holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 5,479,259 | $853,997,354 | 4.16% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 9, 2025 |
| June 30, 2025 | 5,451,401 | $940,911,882 | 3.95% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 12, 2025 |
| Sept. 30, 2025 | 5,259,909 | $1,045,722,561 | 4.39% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 12, 2025 |
| Dec. 31, 2025 | 5,185,696 | $1,105,797,733 | 4.61% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 11, 2026 |
| March 31, 2026 | 4,813,440 | $1,100,978,089 | 4.62% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 11, 2026 |
| June 30, 2026 | Absent this quarter | — | — | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 12, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.